<DOC>
	<DOC>NCT00195325</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.</brief_summary>
	<brief_title>Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Documented diagnosis of malignant solid tumor with measurable disease Life expectancy of at least 12 weeks ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2 Recent major surgery, radiation therapy or anticancer treatment History of any other prior malignancy within the last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
</DOC>